US4418076A
Expired / Lapsed
US
⏱️ 0.0 years remaining
7-Oxabicycloheptane hydrazone prostaglandin analogs useful in treating thrombolytic diseases
Assignee: ER Squibb and Sons LLC
•
Filing: 1982-05-03
•
Granted: 1983-11-29
•
Expires: 2002-05-03
Abstract
Abstract 7-Oxabicycloheptane hydrazone prostaglandin analogs are provided having the structural formula ##STR1## and including all stereoisomers thereof. pa The compounds are cardiovascular agents useful, for example, in the treatment of thrombolytic disease.
Inventors
- 👤 Masami Nakane
- 👤 Joyce Reid
- 👤 Martin F. Haslanger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 17:42
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/08; A; A61; A61P; A61P11/00; A61P11/08; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
53 words
A compound having the structural formula ##STR18## and including all stereoisomers thereof wherein A is CH═CH or (CH 2 ) 2 ; m is 1 to 8; R is H or lower alkyl; R 2 is H or lower alkyl; and R 1 is lower alkoxy and x is 3, 4 or 5.
Claim 2
Dependent Claim
53 words
A compound having the structural formula ##STR18## and including all stereoisomers thereof wherein A is CH═CH or (CH 2 ) 2 ; m is 1 to 8; R is H or lower alkyl; R 2 is H or lower alkyl; and R 1 is lower alkoxy and x is 3, 4 or 5.
Claim 3
Dependent Claim
21 words
The compound as defined in claim 1 having the formula ##STR19## wherein R 1 is lower alkoxy including all stereoisomers thereof.
Claim 4
Dependent Claim
12 words
The compound as defined in claim 1 having the formula ##STR20## .
Claim 5
Dependent Claim
11 words
The compound as defined in claim 1 having the formula ##STR21##
Claim 6
Dependent Claim
19 words
The compound as defined in claim 1 wherein A--(CH 2 ) m --COOR is --CH═CH--(CH 2 ) 3 --COOH.
Claim 7
Dependent Claim
23 words
The compound as defined in claim 1 having the name [1β,2α(5Z),3β,4β]-7-[3-[[(propoxycarbonyl)hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1β,2α(5Z),3α,4β]-7-[3-[[(propoxycarbonyl)hydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each, or stereoisomers thereof.
Claim 8
Dependent Claim
19 words
The compound as defined in claim 1 having the name [1β,2α(5Z),3α,4β]-7-[3-[[(propoxycarbonyl)methylhydrazono]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or its methyl ester of stereoisomers thereof.
Claim 9
Dependent Claim
18 words
The compound as defined in claim 1 having the name [1β,2α(5Z),3α,4β]-7-[3-[[(2-oxo-1-piperidinyl)imino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid, its methyl ester, or stereoisomers thereof.
Claim 10
Dependent Claim
36 words
A method of inhibiting platelet aggregation and bronchoconstriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
26 words
The method as defined in claim 9 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
Claim 12
Dependent Claim
32 words
A composition for inhibiting platelet aggregation and bronchoconstriction comprising an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.
Claim 13
Dependent Claim
30 words
A method of inhibiting platelet aggregation, which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
32 words
A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US4143054A
Cited
US4187236A
Cited
US4220594A
Cited
US4254044A
Cited
GB2039909B
Cited
US4228180A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-11-28 | 1987-05-30 | 1987-11-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-11-28 | 1991-05-30 | 1991-11-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-11-28 | 1995-05-30 | 1995-11-29 | $7700.00 | Window Closed / Lapsed |